Tango Therapeutics reports Q4 2022 net loss $29.1M; TNG462 gets Fast Track; appoints new R&D President

Tango Therapeutics, Inc.

Net loss of $29.1M in Q4 2022 ($0.33/share) vs $22.0M ($0.25) in Q4 2021; FY2022 net loss $108.2M ($1.23) vs $58.2M ($0.94).
Cash of $366.1M at Dec 31, 2022 expected to fund operations into 2025.
FDA granted Fast Track Designation to TNG462, a next-gen MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers.
Adam Crystal, M.D., Ph.D. appointed President of Research and Development in February 2023.
Upcoming: TNG908 proof-of-mechanism update Q2 2023; IND filings for TNG260 (H1 2023) and TNG348 (mid-2023).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tango Therapeutics, Inc. reported financial results for the full year ended December 31, 2022.

Period: the full year ended December 31, 2022
Result: reported results

Exact text from the filing

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2022, and provided business highlights.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tango Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $6.4 million.

Period: the fourth quarter ended December 31, 2022
Revenue: $6.4 million
Result: reported results

Exact text from the filing

Collaboration revenue was $6.4 million for the three months ended December 31, 2022

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-009852

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.